Gliomas are the most common brain tumors of the central nervous system. In this study, we investigated the molecular mechanisms and biological function of SIRT6 in human gliomas. The expression levels of SIRT6 in glioma tissues and cells were analyzed by qRT-PCR and western blot analysis. CCK8 and clonogenicity assays were performed to detect the cell proliferation. Furthermore, the migration and invasion of glioma cells were examined by transwell assays. It was found that the expression of SIRT6 was significantly lower in human glioma tissues or cell lines compared with the normal brain tissue or NHA. Up-regulated SIRT6 significantly decreased cell proliferation, migration and invasion of U87 and U251 cells. By contrast, knockdown of SIRT6 dramatically increased cell proliferation, migration and invasion of U87 and U251 cells. Moreover, over expression of NOTCH3 significantly increased the cell proliferation, migration, and invasion of U87 and U251 cells. However, these effects were abolished after overexpression of SIRT6. These results suggest that SIRT6 may suppress cell proliferation, migration, and invasion via inhibition of the NOTCH3 signaling pathway in glioma.
Introduction
Gliomas are the most common brain tumors of the central nervous system in adults [1] . The histopathological hallmarks of gliomas are rapid cell proliferation and diffuse brain migration and invasion [2] . Moreover, it was reported that during 2 years of diagnosis over 70% of the patients died of the disease [3] . Although various treatments, such as chemotherapy, radiotherapy, and surgery have been adopted, most glioma patients have short overall survival time [4] . Therefore, there is an urgent need to better understand the molecule mechanism involved in cell proliferation, migration and invasion of glioma in order to develop novel and effective therapies for patients with glioma.
SIRT6 is a member of the NAD + -dependent deacetylase SIRTUIN family [5] . A previous study has indicated SIRT6 is involved in many biological processes, including genomic stability, metabolism, senescence, inflammation, and carcinogenesis [6] . Recent studies have revealed that the function of SIRT6 in cancer is complex, which acts as both oncogene and tumor suppressor gene [7] [8] [9] [10] [11] [12] . Zhang et al. [7] showed that SIRT6 expression was significantly down-regulated in human ovarian cancer tissues compared with that in normal tissues and over expression of SIRT6 inhibited the proliferation of ovarian cancer cells, while knockdown of SIRT6 enhanced cell growth, which demonstrated that SIRT6 functions as a tumor suppressor gene. In contrast, SIRT6 has been reported to be overexpressed in the hepatocellular carcinoma and prostate cancer [8, 9] . However, the molecular mechanism of SIRT6 in gliomas is largely unknown.
During tumorigenesis, Notch signaling is often dysregulated [13] . NOTCH3, a type of Notch receptor, plays an important role in promoting tumorigenesis [14] . The oncogenic function of NOTCH3 has been documented in breast cancer [15] , non-small cell lung cancer [16] , colorectal cancer [17] , and so on. Oncogenic properties of NOTCH3 include increased proliferation, migration and invasion [18, 19] . A previous study indicated that NOTCH3 plays a critical role in glioma cell proliferation, cell migration, and invasion [20] . Moreover, it has been demonstrated that NOTCH3 induces glioma cell invasion and proliferation via the activation of cyclin D1 (CCND1) and epidermal growth factor receptor (EGFR) gene expression [20] .
In the present study, we investigated the molecular mechanisms and biological function of SIRT6 in human gliomas.
Materials and Methods

Human glioma tissue samples
Human tissue samples of normal brain and glioma were obtained from the Department of Neurosurgery, Fudan University Shanghai Cancer Center (Shanghai, China). A total of 25 glioma samples and 15 normal brain tissues derived from the temporal lobes and saddle area of the patients with arachnoid cyst were used in this study. Samples were collected during surgery and immediately frozen in liquid nitrogen for subsequent use. Written informed consent was obtained from each patient before surgery. This study was approved by the Medical Ethics Committee of the Fudan University Shanghai Cancer Center.
Cell culture
Human glioma cell lines U251, U87, LN18, and A172, and normal human astrocyte cell line NHA were purchased from Cell Library of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in complete DMEM (Gibco, Carlsbad, USA) supplemented with 100 U/ml penicillin and streptomycin (Gibco), 10% fetal bovine serum (FBS) in a 5% CO 2 humidified chamber at 37°C.
Plasmid construction and transfection
Total cDNA obtained from reverse transcription of U87 cells mRNA was used to amplify SIRT6 and NOTCH3 coding sequences by PCR. The SIRT6 and NOTCH3 was cloned into pcDNA3.1 (Invitrogen, Carlsbad, USA), generating pcDNA3.1-SIRT6 and pcDNA3.1-NOTCH3.
Small-interfering RNA (siRNA) targeting on SIRT6 and the nontarget scramble siRNA (si-Control) were designed and synthesized by GenePharma (Shanghai, China). All cell transfections were performed using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions [21] . siRNA target sequences are as follows: si-SIRT6 1#: AAGAATGTGCCAAGTGTAAGA; si-SIRT6 2#: CCGGCTCTGCACCGTGGCTAA. si-Control: UUCU CCGAACGUGUCACGUTT.
CCK8 assay
Cell proliferation was assessed by CCK8 assay. Transfected cells were seeded in a 96-well plate and cultured for different time. After the incubation period, 10 μl of CCK8 reagent (Keygen, Nanjing, China) was added to each well. Cells were incubated for 1 h at 37°C. The absorbance was then measured at 450 nm using a microplate reader (Multiskan Mk3, Helsinki, Finland).
Soft agar colony formation assay
The cells were suspended in 1.5 ml complete medium which was supplemented with 0.45% agarose (Invitrogen). Then the cells were placed in 35 mm tissue culture plates plus 1.5 ml complete medium and 0.75% agarose on the bottom layer. After incubation for 2 weeks, cell colonies were stained with 0.005% crystal violet and visualized using a microscope. And the colony number in each well was calculated. Relative colony number was represented by normalization of the colony number to that of the cell line transfected with the control vector. 
Cell migration and invasion assay
Cell migration assay was carried out using a transwell chamber (8.0 μm pore size; Costar, Cambridge, USA). In brief, the medium with 10% FBS was added to the lower chamber. And cells were placed in the upper chamber and incubated for 24 h. After that, the cells were fixed with 100% methanol and stained with 1% crystal violet and counted immediately after staining. For the cell invasion assay, the transwell membrane was pre-coated with 30 μl of Matrigel (Corning, Corning, USA) and the other protocols were the same as those described above.
Quantitative real-time PCR
Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions [22] . cDNA was synthesized using a PrimeScript RT reagent kit (TaKaRa, Dalian, China). The qPCR amplification was carried out on an ABI 7500 Fast Real Time PCR system (Applied Biosystems, Foster City, USA). GAPDH was used as an internal control. The primers were as follows: SIRT6-F:
5′-TACGCGGACAAGGGCAAG-3′; SIRT6-R: 5′-ACTTGGGGGCC AGACCTCGC-3′; NOTCH3-F: 5′-TGTGAAGTGAACGTGGAC GACTGT-3′; NOTCH3-R: 5′-AGGGCACTGGCAGTTATAGGT GTT-3′; GAPDH-F: 5′-GCACCGTCAAGGCTGAGAAC-3′; GAPDH-R: 5′-TGGTGAAGACGCCAGTGGA-3′. The PCR was carried out at 95°C for 5 min, followed by 40 cycles at 95°C for 10 s and 60°C for 30 s. The mRNA expression levels were normalized to GAPDH expression. The 2 −ΔΔCq method was used to calculate the expression levels.
Western blot analysis
The tissues or cells were lysed as described previously [23] . After that, proteins were separated on 10% sodium dodecyl sulphfatepolyacrylamide gel electrophoresis (SDS-PAGE) (Beyotime Institute of Biotechnology, Shanghai, China). And, then proteins were transferred onto PVDF membranes (Millipore, Billerica, USA). Subsequently, PVDF membranes were incubated with primary antibodies against SIRT6, NOTCH3, CCND1, EGFR, or GAPDH, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Chemiluminescent detection was visualized by ECL Detection Reagents (Amersham Bioscience, Buckinghamshire, UK).
Statistical analyses
Data were presented as the mean ± standard deviation (SD). Statistical analysis was performed using the software of SPSS 17.0 (SPSS Inc, Chicago, USA). And comparisons between two groups were evaluated by Student's t-test. P < 0.05 was considered statistically significant.
Results
Down-regulation of SIRT6 in glioma tissues and cells
To determine whether SIRT6 is involved in the development of glioma, we first detected the expression of SIRT6 in normal brain tissue samples and glioma tissues by qRT-PCR analysis and western blot analysis. It was found that the mRNA and protein expression levels of SIRT6 were significantly down-regulated in glioma tissues compared with those in normal brain tissues (Fig. 1A) . In addition, the mRNA and protein expression levels of SIRT6 were also decreased in several human glioma cell lines when compared with those in NHA (Fig. 1B) . These results suggested that the expression of SIRT6 was down-regulated in glioma tissues and cell lines.
Over-expression of SIRT6 reduces the proliferation, migration, and invasion of U87 and U251 cells
In order to evaluate the biological role of SIRT6 in glioma, U87, and U251 cells were transfected with plasmids encoding SIRT6 ( Fig. 2A,F) . CCK8 and clonogenicity assays showed that overexpression of SIRT6 dramatically inhibited the cell proliferation compared with the control group (Fig. 2B,C 
,G,H).
Since invasiveness is a pathophysiological feature of human gliomas, the effect of SIRT6 on the migration and invasion of glioma cells were also examined by transwell assays. The transwell assay showed that over expression of SIRT6 significantly reduced the migratory and invasive abilities of U87 and U251 cells (Fig. 2D,E,I ,J). Inhibition of SIRT6 promotes the proliferation, migration, and invasion of U87 and U251 cells
Next, we analyzed whether SIRT6 knockdown in U87 and U251 cells affects the cell proliferation. The expression of SIRT6 was silenced by si-SIRT6 1# or si-SIRT6 2# in U87 and U251 cells, which was confirmed by western blot analysis ( Supplementary  Fig. S1 ). As si-SIRT6 1#-transfected U87 and U251 cells exhibited lower SIRT6 expression compared with si-SIRT6 2#-transfected cells, si-SIRT6 1# was selected to silence SIRT6 expression for the subsequent assays (Fig. 3A,F) . As expected, the cell proliferation was significantly elevated after SIRT6 knockdown in U87 and U251 cells (Fig. 3B,C,G,H) . In addition, down-regulation of SIRT6 was found to markedly promote the migratory and invasive abilities of U87 and U251 cells (Fig. 3D,E,I ,J).
SIRT6 inhibits NOTCH3 expression in U87 cells
To evaluate whether NOTCH3 has a role in the function of SIRT6, we analyzed the effect of SIRT6 overexpression on NOTCH3 expression. Intriguingly, qPCR and western blot analysis showed that over expression of SIRT6 decreased the expression of NOTCH3 in U87 cells (Fig. 4A,B) . By contrast, down-regulation of SIRT6 resulted in elevated expression of NOTCH3 at the mRNA and protein levels (Fig. 4C,D) . Collectively, these results demonstrated that SIRT6 negatively regulated the expression of NOTCH3 in U87 cells.
SIRT6 inhibits the cell proliferation, migration and invasion via regulation of NOTCH3 in U87 cells
To further investigate whether SIRT6 inhibit cell proliferation, migration, and invasion by NOTCH3, plasmids encoding NOTCH3 was transfected into U87 cells (Fig. 5A) . However, no change of the expression level of SIRT6 protein was observed after over expression of NOTCH3 (Fig. 5A) . As a result, the overexpression of NOTCH3 significantly increased the cell proliferation, migration, and invasion of U87 cells. However, these effects were abolished after over expression of SIRT6 (Fig. 5B-E) . These data suggested that SIRT6 suppressed the cell proliferation, migration, and invasion of U87 cells through negative regulation of NOTCH3.
SIRT6 regulates the expression of NOTCH3, which modulates the expression of CCND1 and EGFR
To further investigate the role of NOTCH3 signaling in glioma, the expression levels of potential NOTCH3 targets were assessed by western blot analysis. As shown in Fig. 5F , overexpression of SIRT6 notably decreased the expression levels of CCND1 and EGFR in U87 cells. On the contrary, overexpression of NOTCH3 significantly increased the protein levels of CCND1 and EGFR, which were reversed by overexpression of SIRT6. These findings indicated that SIRT6 might regulate the expression of NOTCH3, which modulated the CCND1 and EGFR expression.
Discussion
During the past several years, the role of SIRT6 in tumorigenesis has been deeply studied. SIRT6 is overexpressed in several cancers, including prostate cancer, skin squamous cell carcinoma, and endometrioid carcinomas [9, 24, 25] . In contrast, SIRT6 is downregulated in pancreatic cancer and colorectal carcinoma [26, 27] . In breast cancer, high expression of SIRT6 is predictive of poor prognosis [28] . However, many SIRT6 biological functions are associated with anti-cancer effects, including its role in cancer cell apoptosis, and reducing cell viability [29] . Therefore, the role of SIRT6 in cancer is complex, with some studies supporting a tumorsuppressive role, and other cancer-promoting role. However, the molecular mechanisms of SIRT6 activity in glioma are still largely unknown. In a recent study, Chen et al. [30] showed that SIRT6 decreased in human glioma tissues cell lines. Feng et al. [31] observed notable down-regulation of SIRT6 in the glioblastoma multiforme (GBM) and overexpression of SIRT6 reduced cell proliferation in the cultured glioma cells. In line with the results above, our results showed that knockdown of SIRT6 promoted cell proliferation, migration and invasion, suggesting that SIRT6 may be a tumor suppressor in glioma.
The activation of Notch signaling has been demonstrated to be involved in carcinogenesis [32] . Moreover, it has been reported that NOTCH3 activation promotes the formation of invasive glioma [33] . In addition, NOTCH3 promotes glioma cell proliferation, migration, and invasion [20] . Our data showed that overexpression of NOTCH3 elevated the proliferation, migration, and invasion of U87 and U251 cells, which was in agreement with the previous studies.
A recent study has demonstrated that SIRT6 inhibits cell proliferation via inhibition of Notch3 expression in the ovarian cancer [7] . Our study revealed that SIRT6 could significantly decrease the expression of NOTCH3. In addition, the overexpression of SIRT6 abolished the promoting effect of NOTCH3 on cell proliferation, migration and invasion. These results suggested that the effect of SIRT6 on glioma cells might be mediated by NOTCH3.
CCND1 is a vital regulator of cell cycle progression [34] . Downregulation of CCND1 results in the accumulation of the glioma cells at G0/G1, which might be the underlying mechanism of low cell proliferation of glioma cells upon knockdown of NOTCH3 [35] . Moreover, EGFR overexpression promotes cell proliferation, migration and is an indicator of bad prognosis [36] . Zhang et al. [7] reported that NOTCH3 could promote glioma cell proliferation, migration, and invasion through activation of CCND1 and EGFR. Our results showed that overexpression of NOTCH3 obviously increased the protein levels of CCND1 and EGFR. However, the effects were reversed by overexpression of SIRT6. Therefore, SIRT6 may regulate NOTCH3 expression by inhibiting the CCND1 and EGFR expression.
In conclusion, we demonstrated that SIRT6 was down-regulated in human glioma tissues and cell lines. Moreover, SIRT6 might inhibit cell proliferation, migration and invasion via inhibition of the NOTCH3 signaling pathway in glioma. These findings suggest that SIRT6 may act as potential drug candidates for glioma therapy.
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